Book a demo
Skip to content

Stonewake Monitoring

Intellia Therapeutics files 8-K covering new debt obligation

Intellia Therapeutics, Inc. submitted a Form 8-K on September 4, 2026 that includes disclosure items related to a debt arrangement.

Export financeUSAPublished · 2 sourced facts

Intellia Therapeutics, Inc., a Delaware-incorporated company listed on Nasdaq under the ticker NTLA, filed an 8-K with the SEC on September 4, 2026.[1][2]

The filing carries accession number 0001193125-26-383645 and its matched document is d110798d8k.htm.[1]

The 8-K covers items 1.01, 2.03, 7.01, and 9.01, and its period ending matches the September 4, 2026 filing date.[1]

The company is registered under CIK 0001652130 and is classified in the in vitro and in vivo diagnostic substances industry.[2]

Sources

  1. [1]SEC EDGAR: 8-K, 0001193125-26-383645, 4 Sep 2026
  2. [2]SEC EDGAR: CIK 0001652130, Intellia Therapeutics, Inc.

SEC EDGAR

← All briefs